Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review
Type de publicationJournal Article
Year of Publication2018
AuteursDeshayes S, Georgin-Lavialle S, Hot A, Durel C-A, Hachulla E, Rouanes N, Audia S, Le Gallou T, Quartier P, Urbanski G, Messer L, Klein S, de Boysson H, Bienvenu B, Grateau G, Aouba A
JournalJOURNAL OF RHEUMATOLOGY
Volume45
Pagination425-429
Date PublishedMAR 1
Type of ArticleReview
ISSN0315-162X
Mots-clésCanakinumab, HEREDITARY AUTOINFLAMMATORY DISEASES, INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN ANAKINRA, MEVALONATE KINASE DEFICIENCY
Résumé

Objective. To report efficacy and tolerance of interleukin 1 blockade in adult patients with mevalonate kinase deficiency (MKD). Methods. We retrospectively collected data on 13 patients with MKD who had received anakinra (n = 10) and canakinumab (n = 7). Results. Anakinra resulted in complete or partial remission in 3/10 and 5/10 patients, respectively, and no efficacy in 2/10, but a switch to canakinumab led to partial remission. Canakinumab resulted in complete or partial remission in 3/7 and 4/7 patients, respectively. Conclusion. These data support frequent partial responses, showing a better response with canakinumab. The genotype and therapeutic outcomes correlation should help in the personalization of treatment.
DOI10.3899/jrheum.170684